vs

Side-by-side financial comparison of EXTREME NETWORKS INC (EXTR) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $316.9M, roughly 2.0× EXTREME NETWORKS INC). Royalty Pharma plc runs the higher net margin — 34.4% vs 3.3%, a 31.1% gap on every dollar of revenue. On growth, EXTREME NETWORKS INC posted the faster year-over-year revenue change (11.4% vs 4.8%). Over the past eight quarters, EXTREME NETWORKS INC's revenue compounded faster (11.1% CAGR vs 4.6%).

Extreme Networks, Inc. is an American networking company based in Morrisville, North Carolina. Extreme Networks designs, develops, and manufactures wired and wireless network infrastructure equipment and develops the software for network management, policy, analytics, security and access controls.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

EXTR vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
2.0× larger
RPRX
$622.0M
$316.9M
EXTR
Growing faster (revenue YoY)
EXTR
EXTR
+6.6% gap
EXTR
11.4%
4.8%
RPRX
Higher net margin
RPRX
RPRX
31.1% more per $
RPRX
34.4%
3.3%
EXTR
Faster 2-yr revenue CAGR
EXTR
EXTR
Annualised
EXTR
11.1%
4.6%
RPRX

Income Statement — Q4 FY2026 vs Q4 FY2025

Metric
EXTR
EXTR
RPRX
RPRX
Revenue
$316.9M
$622.0M
Net Profit
$10.6M
$214.2M
Gross Margin
61.7%
Operating Margin
5.5%
62.4%
Net Margin
3.3%
34.4%
Revenue YoY
11.4%
4.8%
Net Profit YoY
202.9%
2.9%
EPS (diluted)
$0.08
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXTR
EXTR
RPRX
RPRX
Q2 26
$316.9M
Q4 25
$317.9M
$622.0M
Q3 25
$310.2M
$609.3M
Q2 25
$307.0M
$578.7M
Q1 25
$284.5M
$568.2M
Q4 24
$279.4M
$593.6M
Q3 24
$269.2M
$564.7M
Q2 24
$256.7M
$537.3M
Net Profit
EXTR
EXTR
RPRX
RPRX
Q2 26
$10.6M
Q4 25
$7.9M
$214.2M
Q3 25
$5.6M
$288.2M
Q2 25
$-7.8M
$30.2M
Q1 25
$3.5M
$238.3M
Q4 24
$7.4M
$208.2M
Q3 24
$-10.5M
$544.0M
Q2 24
$-54.2M
$102.0M
Gross Margin
EXTR
EXTR
RPRX
RPRX
Q2 26
61.7%
Q4 25
61.4%
Q3 25
60.6%
Q2 25
61.6%
Q1 25
61.7%
Q4 24
62.7%
Q3 24
63.0%
Q2 24
44.7%
Operating Margin
EXTR
EXTR
RPRX
RPRX
Q2 26
5.5%
Q4 25
4.1%
62.4%
Q3 25
3.6%
70.1%
Q2 25
-0.4%
36.3%
Q1 25
3.6%
94.0%
Q4 24
4.5%
60.9%
Q3 24
-1.8%
Q2 24
-19.1%
50.2%
Net Margin
EXTR
EXTR
RPRX
RPRX
Q2 26
3.3%
Q4 25
2.5%
34.4%
Q3 25
1.8%
47.3%
Q2 25
-2.5%
5.2%
Q1 25
1.2%
41.9%
Q4 24
2.6%
35.1%
Q3 24
-3.9%
96.3%
Q2 24
-21.1%
19.0%
EPS (diluted)
EXTR
EXTR
RPRX
RPRX
Q2 26
$0.08
Q4 25
$0.06
$0.49
Q3 25
$0.04
$0.67
Q2 25
$-0.07
$0.07
Q1 25
$0.03
$0.55
Q4 24
$0.06
$0.46
Q3 24
$-0.08
$1.21
Q2 24
$-0.40
$0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXTR
EXTR
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$210.1M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$9.7B
Total Assets
$1.2B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXTR
EXTR
RPRX
RPRX
Q2 26
$210.1M
Q4 25
$219.8M
$618.7M
Q3 25
$209.0M
$938.9M
Q2 25
$231.7M
$631.9M
Q1 25
$185.5M
$1.1B
Q4 24
$170.3M
$929.0M
Q3 24
$159.5M
$950.1M
Q2 24
$156.7M
$1.8B
Total Debt
EXTR
EXTR
RPRX
RPRX
Q2 26
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$180.0M
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$190.0M
$7.6B
Stockholders' Equity
EXTR
EXTR
RPRX
RPRX
Q2 26
Q4 25
$95.9M
$9.7B
Q3 25
$68.6M
$9.6B
Q2 25
$65.6M
$9.5B
Q1 25
$71.7M
$9.8B
Q4 24
$51.2M
$10.3B
Q3 24
$32.7M
$10.3B
Q2 24
$25.3M
$9.8B
Total Assets
EXTR
EXTR
RPRX
RPRX
Q2 26
$1.2B
Q4 25
$1.2B
$19.6B
Q3 25
$1.2B
$19.3B
Q2 25
$1.2B
$18.3B
Q1 25
$1.1B
$17.6B
Q4 24
$1.1B
$18.2B
Q3 24
$1.1B
$18.0B
Q2 24
$1.0B
$17.7B
Debt / Equity
EXTR
EXTR
RPRX
RPRX
Q2 26
Q4 25
0.92×
Q3 25
0.93×
Q2 25
2.74×
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
7.52×
0.78×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXTR
EXTR
RPRX
RPRX
Operating Cash FlowLast quarter
$50.3M
$827.1M
Free Cash FlowOCF − Capex
$7.8M
FCF MarginFCF / Revenue
2.5%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
4.75×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$105.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXTR
EXTR
RPRX
RPRX
Q2 26
$50.3M
Q4 25
$50.1M
$827.1M
Q3 25
$-14.0M
$702.6M
Q2 25
$81.9M
$364.0M
Q1 25
$30.0M
$596.1M
Q4 24
$21.5M
$742.5M
Q3 24
$18.6M
$703.6M
Q2 24
$15.5M
$658.2M
Free Cash Flow
EXTR
EXTR
RPRX
RPRX
Q2 26
$7.8M
Q4 25
$43.0M
Q3 25
$-20.9M
Q2 25
$75.3M
Q1 25
$24.2M
Q4 24
$16.1M
Q3 24
$11.7M
Q2 24
$11.0M
FCF Margin
EXTR
EXTR
RPRX
RPRX
Q2 26
2.5%
Q4 25
13.5%
Q3 25
-6.7%
Q2 25
24.5%
Q1 25
8.5%
Q4 24
5.8%
Q3 24
4.3%
Q2 24
4.3%
Capex Intensity
EXTR
EXTR
RPRX
RPRX
Q2 26
Q4 25
2.2%
Q3 25
2.2%
Q2 25
2.2%
Q1 25
2.0%
Q4 24
1.9%
Q3 24
2.6%
Q2 24
1.7%
Cash Conversion
EXTR
EXTR
RPRX
RPRX
Q2 26
4.75×
Q4 25
6.37×
3.86×
Q3 25
-2.49×
2.44×
Q2 25
12.06×
Q1 25
8.67×
2.50×
Q4 24
2.92×
3.57×
Q3 24
1.29×
Q2 24
6.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXTR
EXTR

Product$199.4M63%
Subscription and support$117.5M37%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons